Literature DB >> 29345063

Immunotherapy: It is not just for cancer anymore.

Lyle L Moldawer1, Richard Hotchkiss2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29345063     DOI： 10.1002/JLB.4CE1117-447

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


× No keyword cloud information.
  4 in total

Review 1.  Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery.

Authors:  Philip A Efron; Alicia M Mohr; Azra Bihorac; Hiroyuki Horiguchi; McKenzie K Hollen; Mark S Segal; Henry V Baker; Christiaan Leeuwenburgh; Lyle L Moldawer; Frederick A Moore; Scott C Brakenridge
Journal:  Surgery       Date:  2018-05-26       Impact factor: 3.982

2.  Frontline Science: OX40 agonistic antibody reverses immune suppression and improves survival in sepsis.

Authors:  Jacqueline Unsinger; Andrew H Walton; Teresa Blood; Daniel J Tenney; Michael Quigley; Anne M Drewry; Richard S Hotchkiss
Journal:  J Leukoc Biol       Date:  2020-08-17       Impact factor: 4.962

3.  Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells.

Authors:  Claudia Carenza; Francesca Calcaterra; Ferdinando Oriolo; Clara Di Vito; Marta Ubezio; Matteo Giovanni Della Porta; Domenico Mavilio; Silvia Della Bella
Journal:  Front Immunol       Date:  2019-06-11       Impact factor: 7.561

4.  Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike.

Authors:  Eizo Watanabe; Lukose K Thampy; Richard S Hotchkiss
Journal:  Acute Med Surg       Date:  2018-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.